Published in AIDS Weekly, October 2nd, 2006
The funds will be used for the development of initial clinical candidates and will advance the cancer program to the point of filing an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA).
H.I.G. Ventures led the round joined by new investors The Aurora Funds, CM Capital, SR One and MedImmune Ventures, Inc. Existing investors, Georgia Venture Partners and Centrosome Ventures, also participated, along with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.